Literature DB >> 28130400

Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST.

Maria A Pantaleo1,2, Milena Urbini2, Valentina Indio2, Gloria Ravegnini3, Margherita Nannini4, Matilde De Luca2, Giuseppe Tarantino2, Sabrina Angelini3, Alessandro Gronchi5, Bruno Vincenzi6, Giovanni Grignani7, Chiara Colombo5, Elena Fumagalli5, Lidia Gatto4, Maristella Saponara4, Manuela Ianni2, Paola Paterini8, Donatella Santini9, M Giulia Pirini9, Claudio Ceccarelli4, Annalisa Altimari9, Elisa Gruppioni9, Salvatore L Renne5, Paola Collini5, Silvia Stacchiotti5, Giovanni Brandi4, Paolo G Casali5, Antonio D Pinna10, Annalisa Astolfi2, Guido Biasco4,2.   

Abstract

Quadruple wild-type (WT) gastrointestinal stromal tumor (GIST) is a genomic subgroup lacking KIT/PDGFRA/RAS pathway mutations, with an intact succinate dehydrogenase (SDH) complex. The aim of this work is to perform a wide comprehensive genomic study on quadruple WT GIST to improve the characterization of these patients. We selected 14 clinical cases of quadruple WT GIST, of which nine cases showed sufficient DNA quality for whole exome sequencing (WES). NF1 alterations were identified directly by WES. Gene expression from whole transcriptome sequencing (WTS) and miRNA profiling were performed using fresh-frozen, quadruple WT GIST tissue specimens and compared with SDH and KIT/PDGFRA-mutant GIST. WES identified an average of 18 somatic mutations per sample. The most relevant somatic oncogenic mutations identified were in TP53, MEN1, MAX, FGF1R, CHD4, and CTDNN2. No somatic alterations in NF1 were identified in the analyzed cohort. A total of 247 mRNA transcripts and 66 miRNAs were differentially expressed specifically in quadruple WT GIST. Overexpression of specific molecular markers (COL22A1 and CALCRL) and genes involved in neural and neuroendocrine lineage (ASCL1, Family B GPCRs) were detected and further supported by predicted miRNA target analysis. Quadruple WT GIST show a specific genetic signature that deviates significantly from that of KIT/PDGFRA-mutant and SDH-mutant GIST. Mutations in MEN1 and MAX genes, a neural-committed phenotype and upregulation of the master neuroendocrine regulator ASCL1, support a genetic similarity with neuroendocrine tumors, with whom they also share the great variability in oncogenic driver genes.Implications: This study provides novel insights into the biology of quadruple WT GIST that potentially resembles neuroendocrine tumors and should promote the development of specific therapeutic approaches. Mol Cancer Res; 15(5); 553-62. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28130400     DOI: 10.1158/1541-7786.MCR-16-0376

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  22 in total

1.  Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

Authors:  Franz X Schaub; Varsha Dhankani; Ashton C Berger; Mihir Trivedi; Anne B Richardson; Reid Shaw; Wei Zhao; Xiaoyang Zhang; Andrea Ventura; Yuexin Liu; Donald E Ayer; Peter J Hurlin; Andrew D Cherniack; Robert N Eisenman; Brady Bernard; Carla Grandori
Journal:  Cell Syst       Date:  2018-03-28       Impact factor: 10.304

2.  A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy.

Authors:  Lindsey M Charo; Adam M Burgoyne; Paul T Fanta; Hitendra Patel; Juliann Chmielecki; Jason K Sicklick; Michael T McHale
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

Review 3.  Gastrointestinal Stromal Tumors.

Authors:  Margaret von Mehren; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

Review 4.  Molecular characterization and pathogenesis of gastrointestinal stromal tumor.

Authors:  Takeshi Niinuma; Hiromu Suzuki; Tamotsu Sugai
Journal:  Transl Gastroenterol Hepatol       Date:  2018-01-09

5.  Risk stratification of gastrointestinal stromal tumors by Nanostring gene expression profiling.

Authors:  Klaudia Nowak; Kim Formenti; Jingyang Huang; Gilbert Bigras; Quincy Chu; Benjamin A Adam; Iyare Izevbaye
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-28       Impact factor: 4.553

Review 6.  Normal and Neoplastic Growth Suppression by the Extended Myc Network.

Authors:  Edward V Prochownik; Huabo Wang
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

7.  FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.

Authors:  Josephine K Dermawan; Chad M Vanderbilt; Jason C Chang; Brian R Untch; Samuel Singer; Ping Chi; William D Tap; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2022-02-22       Impact factor: 4.263

Review 8.  Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency.

Authors:  Georgia Pitsava; Nikolaos Settas; Fabio R Faucz; Constantine A Stratakis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-03       Impact factor: 5.555

9.  The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST).

Authors:  Margherita Nannini; Milena Urbini; Annalisa Astolfi; Guido Biasco; Maria A Pantaleo
Journal:  J Transl Med       Date:  2017-05-23       Impact factor: 5.531

10.  Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

Authors:  David S Moura; Rafael Ramos; Antonio Fernandez-Serra; Teresa Serrano; Julia Cruz; Ramiro Alvarez-Alegret; Rosa Ortiz-Duran; Luis Vicioso; Maria Luisa Gomez-Dorronsoro; Xavier Garcia Del Muro; Javier Martinez-Trufero; Jordi Rubio-Casadevall; Isabel Sevilla; Nuria Lainez; Antonio Gutierrez; Cesar Serrano; Maria Lopez-Alvarez; Nadia Hindi; Miguel Taron; José Antonio López-Guerrero; Javier Martin-Broto
Journal:  Oncotarget       Date:  2018-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.